Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

(2009) Agnes Bénardeau et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

(2009) Robert R Henry et al.   LANCET

Heart Disease and Stroke Statistics—2009 Update

(2008) et al.   CIRCULATION

Benefit of Adding Pioglitazone to Successful Statin Therapy in Nondiabetic Patients With Coronary Artery Disease

(2008) Koichi Sugamura et al.   CIRCULATION JOURNAL

Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters: Focus on Organic Anion Transporting Polypeptides and Organic Cation Transporter 1

(2008) I. Bachmakov et al.   DIABETES

Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk

(2008) Thomas Forst et al.   Diabetes & Vascular Disease Research

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE